Clinical Trial Update: KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial [EARLY_Phase 1]

View source ↗

Summary

KSD-101 Therapy for EBV-associated Lymphomas, an exploratory early-phase trial, has been withdrawn. The sponsor is Kousai Bio Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-associated Lymphomas

Drugs mentioned

• KSD-101 Therapy

Snippet

Sponsor: Kousai Bio Co., Ltd. | Conditions: EBV-associated Lymphomas | EARLY_Phase 1 | Status: WITHDRAWN